PMID- 32479127
OWN - NLM
STAT- MEDLINE
DCOM- 20210129
LR  - 20220415
IS  - 1744-7607 (Electronic)
IS  - 1742-5255 (Linking)
VI  - 16
IP  - 7
DP  - 2020 Jul
TI  - Drug Interactions with Gender-Affirming Hormone Therapy: Focus on Antiretrovirals 
      and Direct Acting Antivirals.
PG  - 565-582
LID - 10.1080/17425255.2020.1777278 [doi]
AB  - INTRODUCTION: Gender-affirming care may include hormonal therapy to attain 
      desired health outcomes in transgender (trans) individuals. To provide safe, 
      affirming medical care for trans patients, health care providers must identify 
      and manage drug-drug interactions (DDIs) between gender affirming hormonal 
      therapy (GAHT) and other medication therapies. AREAS COVERED: This review 
      summarizes available data on DDIs between GAHT and antiretrovirals (ARVs) or 
      hepatitis C direct acting antivirals (DAAs). Potential pharmacokinetic and 
      pharmacodynamic DDIs are predicted based on GAHT, ARV, and DAA pharmacology and 
      adverse event profiles. Clinical management strategies are discussed. EXPERT 
      OPINION: GAHT may be involved in pharmacokinetic and/or pharmacodynamic DDIs. 
      Certain ARV classes (non-nucleoside reverse transcriptase inhibitors, protease 
      inhibitors) may alter GAHT disposition, whereas selected ARVs (unboosted 
      integrase inhibitors, doravirine, or rilpivirine) may have less impact on GAHT. 
      DAAs may interact with GAHT, but the clinical relevance is unclear. ARV- and/or 
      DAA-associated side effects (including depression, cardiovascular disease, 
      hyperlipidemia) are important to consider in the clinical management of trans 
      patients. Clinicians must evaluate potential DDIs and overlapping side effects 
      between ARVs, DAAs and GAHT when providing care for trans patients.
FAU - Cirrincione, Lauren R
AU  - Cirrincione LR
AD  - Department of Pharmacy, University of Washington School of Pharmacy , Seattle, 
      WA, USA.
FAU - Senneker, Tessa
AU  - Senneker T
AD  - Department of Pharmacy, Kingston General Hospital , Kingston, ON, Canada.
FAU - Scarsi, Kimberly
AU  - Scarsi K
AD  - Department of Pharmacy Practice and Science, College of Pharmacy, University of 
      Nebraska Medical Center , Omaha, NE, USA.
FAU - Tseng, Alice
AU  - Tseng A
AD  - Faculty of Pharmacy, University of Toronto , Toronto, ON, Canada.
AD  - University Health Network , Toronto, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200627
PL  - England
TA  - Expert Opin Drug Metab Toxicol
JT  - Expert opinion on drug metabolism & toxicology
JID - 101228422
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Antiviral Agents)
RN  - 0 (Gonadal Steroid Hormones)
SB  - IM
EIN - Expert Opin Drug Metab Toxicol. 2021 Jan 1;:1. PMID: 33386065
MH  - Anti-HIV Agents/*administration & dosage/pharmacokinetics/pharmacology
MH  - Antiviral Agents/*administration & dosage/pharmacokinetics/pharmacology
MH  - Drug Interactions
MH  - Female
MH  - Gonadal Steroid Hormones/*administration & dosage/pharmacokinetics/pharmacology
MH  - HIV Infections/drug therapy
MH  - Hepatitis C/drug therapy
MH  - Humans
MH  - Male
MH  - Transgender Persons
OTO - NOTNLM
OT  - Androgen blockers
OT  - antiretrovirals
OT  - direct acting antivirals
OT  - drug interactions
OT  - estradiol
OT  - gender-affirming therapy
OT  - hepatitis C
OT  - hiv
OT  - testosterone
OT  - transgender care
EDAT- 2020/06/02 06:00
MHDA- 2021/01/30 06:00
CRDT- 2020/06/02 06:00
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2021/01/30 06:00 [medline]
PHST- 2020/06/02 06:00 [entrez]
AID - 10.1080/17425255.2020.1777278 [doi]
PST - ppublish
SO  - Expert Opin Drug Metab Toxicol. 2020 Jul;16(7):565-582. doi: 
      10.1080/17425255.2020.1777278. Epub 2020 Jun 27.